Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease

Radiotherapy and Oncology

Volumn 78, Issue 1, 2006, Pages 1-5

  Shahidi, Mehdi ^a   Kamangari, Nahid ^a   Ashley, Sue ^a   Cunningham, David ^a   Horwich, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemotherapy; Hodgkin's disease; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 31144445165     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2005.10.018     Document Type: Article

References (23)

1. A.F. Abrahamsen, E. Hannisdal, and O. Nome Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution Ann Oncol 7 1996 145 150
2. B.M. Aleman, A.W. van den Belt-Dusebout, W.J. Klokman, H. Bartelint, and F.E. van Leeuwen Long-term cause-specific mortality of patients treated for Hodgkin's disease J Clin Oncol 21 2003 3431 3439
3. G.P. Biti, G. Cimino, and C. Cartoni Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's Disease: eight-year update of an Italian prospective randomized study J Clin Oncol 10 1992 378 382
4. V. Bonfante, S. Viviani, and L. Devizzi Ten-Years experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved field (IFRT) in earlt stage hodgkin's Disease (Hd) ASCO. Thirty-seventh annual meeting, May 12-15, 2001 San Francisco, CA 2001
5. Carde P, Noordijk E, Hagenbeek A, et al., Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favourable clinical stage (CS) I-II Hodgkin's disease: the EORTC-GPMC H7F randomized trial. ASCO, Thirty-third annual meeting, May 17-20, 1997 Denver, CO; 1997.
6. M.J. Crnkovich, K. Leopold, R.T. Hoppe, and P.M. Mauch Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy J Clin Oncol 5 1987 1041 1049
7. M. de Wit, K.H. Bohuslavizki, and R. Buchert 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma Ann Oncol 12 2001 29 37
8. H.S. Kaplan Radical radiation for Hodgkin's disease N Engl J Med 278 1968 1404
9. H.S. Kaplan H.S. Kaplan Hodgkin's disease 1980 Mass: Harvard University Press Cambridge
10. H.S. Kaplan, and S.A. Rosenberg International symposium on Hodgkin's disease. Session 5. Treatment. current status of clinical trials: stanford experience, 1962-72 Natl Cancer Inst Monogr 36 1973 363 371
11. H.S. Kaplan, and S.A. Rosenberg The treatment of Hodgkin's disease Med Clin North Am 50 1966 1591 1610
12. Y.K. Lee, G. Cook, and M.A. Flower Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma Radiother Oncol 73 2004 277 283
13. D.L. Longo, E. Glaststein, and F.L. Duffey Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial J Clin Oncol 9 1991 906 917
14. P.M. Mauch, G.P. Canellos, and L.N. Shulman Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial J Clin Oncol 13 1995 947 952
15. R.M. Meyer, M.K. Gospodarowicz, and J.M. Connors Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J Clin Oncol 23 2005 4634 4642
16. J. Reinders, B. Heijmen, and M.J. Olofsen-van Acht Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up Radiother Oncol 51 1999 35 42
17. A. Rueda, E. Alba, N. Ribelles, I. Sevilla, I. Ruiz, and J. Miramon Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study J Clin Oncol 15 1997 1118 1122
18. Ruffer U, Sieber M, Pfistner B, et al. Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long term side-effects: interim analysis of the HD8 Trial (GHSG). ESMO, VII. International Conference on Malignant Lymphoma, 2-5 June 1999, Lugano, Switzerland; 1999.
19. L. Specht, R. Gray, M. Clarke, and R. Peto Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients, International Hodgkin's Disease Collaborative Group J Clin Oncol 16 1998 830 843
20. D.J. Straus, C.S. Portlock, and J. Qin Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 104 2004 3483 3489
21. A. Swerdlow, J. Barber, and G. Hudson Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment J Clin Oncol 18 2000 498 509
22. A Wirth, M Chao, and J Corry Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients J Clin Oncol 17 1999 230 240
23. J. Yahalom, and P. Mauch The involved field is back: issues in delineating the radiation field in Hodgkin's disease Ann Oncol 13 2002 79 83